Analysts Set ProQR Therapeutics NV (NASDAQ:PRQR) Price Target at $27.00

Shares of ProQR Therapeutics NV (NASDAQ:PRQR) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $25.67.

A number of analysts have recently commented on PRQR shares. Zacks Investment Research upgraded ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research report on Wednesday, August 14th. Royal Bank of Canada reiterated a “buy” rating and set a $27.00 target price on shares of ProQR Therapeutics in a research report on Sunday, August 11th. Chardan Capital set a $25.00 target price on ProQR Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 16th. BidaskClub upgraded ProQR Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 11th. Finally, ValuEngine cut ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th.

Institutional investors and hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. purchased a new position in shares of ProQR Therapeutics during the second quarter worth about $740,000. Altrinsic Global Advisors LLC grew its holdings in shares of ProQR Therapeutics by 9.8% during the first quarter. Altrinsic Global Advisors LLC now owns 199,060 shares of the biopharmaceutical company’s stock worth $2,761,000 after buying an additional 17,700 shares during the last quarter. Swiss National Bank grew its holdings in shares of ProQR Therapeutics by 5.4% during the second quarter. Swiss National Bank now owns 49,100 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 2,500 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of ProQR Therapeutics by 62.3% during the second quarter. Virtus ETF Advisers LLC now owns 24,216 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 9,291 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of ProQR Therapeutics by 23.1% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,535 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,979 shares during the last quarter. Institutional investors and hedge funds own 60.79% of the company’s stock.

ProQR Therapeutics stock traded up $0.01 during midday trading on Friday, reaching $7.04. The company’s stock had a trading volume of 113,408 shares, compared to its average volume of 178,912. The business has a 50-day simple moving average of $7.86 and a 200-day simple moving average of $10.74. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.16. ProQR Therapeutics has a fifty-two week low of $6.73 and a fifty-two week high of $24.00. The company has a market cap of $276.00 million, a P/E ratio of -5.46 and a beta of 0.18.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.11. As a group, equities analysts forecast that ProQR Therapeutics will post -1.58 earnings per share for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Further Reading: Stock Symbols Definition, Examples, Lookup

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit